303 related articles for article (PubMed ID: 29689189)
1. Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis.
Oryan A; Bemani E; Bahrami S
Acta Trop; 2018 Sep; 185():34-41. PubMed ID: 29689189
[TBL] [Abstract][Full Text] [Related]
2. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Benaim B; Garcia CR
Trop Biomed; 2011 Dec; 28(3):471-81. PubMed ID: 22433874
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
4. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.
Serrano-Martín X; Payares G; De Lucca M; Martinez JC; Mendoza-León A; Benaim G
Antimicrob Agents Chemother; 2009 Dec; 53(12):5108-13. PubMed ID: 19805563
[TBL] [Abstract][Full Text] [Related]
5. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: drugs in the clinic, resistance and new developments.
Ouellette M; Drummelsmith J; Papadopoulou B
Drug Resist Updat; 2004; 7(4-5):257-66. PubMed ID: 15533763
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase 1B as a target against leishmaniasis.
D'Annessa I; Castelli S; Desideri A
Mini Rev Med Chem; 2015; 15(3):203-10. PubMed ID: 25769969
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.
Bustamante C; Ochoa R; Asela C; Muskus C
J Comput Aided Mol Des; 2019 Sep; 33(9):845-854. PubMed ID: 31612362
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators.
Loiseau PM; Bories C
Curr Top Med Chem; 2006; 6(5):539-50. PubMed ID: 16719806
[TBL] [Abstract][Full Text] [Related]
11. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
12. Dronedarone: an overview.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Ann Med; 2012 Feb; 44(1):60-72. PubMed ID: 21745093
[TBL] [Abstract][Full Text] [Related]
13. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
14. Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy.
Benaim G; Casanova P; Hernandez-Rodriguez V; Mujica-Gonzalez S; Parra-Gimenez N; Plaza-Rojas L; Concepcion JL; Liu YL; Oldfield E; Paniz-Mondolfi A; Suarez AI
Antimicrob Agents Chemother; 2014; 58(4):2295-303. PubMed ID: 24492373
[TBL] [Abstract][Full Text] [Related]
15. An update on small molecule strategies targeting leishmaniasis.
Kapil S; Singh PK; Silakari O
Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
[TBL] [Abstract][Full Text] [Related]
16. Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
Belur Nagaraj A; Joseph P; Kovalenko O; Wang Q; Xu R; DiFeo A
Gynecol Oncol; 2018 Dec; 151(3):525-532. PubMed ID: 30301560
[TBL] [Abstract][Full Text] [Related]
17. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.
de Macedo-Silva ST; Urbina JA; de Souza W; Rodrigues JC
PLoS One; 2013; 8(12):e83247. PubMed ID: 24376670
[TBL] [Abstract][Full Text] [Related]
19. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
20. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
